Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer expects €11bn group sales in Asia by 2015 but wants premium drug pricing in India

This article was originally published in Scrip

Executive Summary

The Bayer group expects overall sales in Asia to exceed €11 billion by 2015, propelled by an expansion in the group's production, distribution and R&D activities the region. These plans would be backed by spending of about €1.8 billion by 2015 and a 27% increase in Bayer's Asian workforce to about 30,000 by then.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC015242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel